This review provides a focused overview of recent advancements in ncRNA-targeted biosensing interfaces, evaluating their operational frameworks and challenges regarding breast cancer diagnosis and monitoring.
Abstract
Breast cancer is the second most frequent malignancy in women and the fifth primary cause of cancer mortality globally. Although early identification and detection of breast cancer has resulted in decreased death rates, further breakthroughs in prevention, detection, and therapy are needed to enhance results and survival for women suffering from breast cancer, and also to provide a personalized therapeutic strategy Aside from the approximately 2% of the human genome that encodes proteins, a significant portion consists of non-coding RNA (ncRNA) which encompasses microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNA (circRNA), small nucleolar RNA (snoRNA), and PIWI-interacting RNAs (piRNA). So far, a substantial number of ncRNAs have been discovered and shown to be dysregulated in different forms of cancer, like breast cancer. Various modalities for detecting non-coding RNAs (ncRNAs) have been developed, including conventional northern blotting, microarrays, and reverse transcription-quantitative PCR (RT-qPCR). To overcome the structural constraints of these traditional methods, biosensor technologies have emerged as alternative platforms for the non-invasive, sensitive, and rapid quantification of oncogenic ncRNAs. Depending on the signal-transduction mechanism, these platforms are primarily categorized into electrochemical, optical, and field-effect transistor (FET)-based biosensors. This review provides a focused overview of recent advancements in ncRNA-targeted biosensing interfaces, evaluating their operational frameworks and challenges regarding breast cancer diagnosis and monitoring.
Prostate cancer (PCa) is the second most prevalent malignancy and a leading cause of can- cer-related mortality in males worldwide. Despite advancements in therapeutic strategies, such as radical prostatectomy, radiotherapy, androgen deprivation therapy (ADT), and chemotherapy, treatment outcomes for metastatic castrat...
Dharanidharan Dhanabalan, N. Shanmugam· Basic & Clinical Cancer...· 0 citations
The present review focuses on the significance of ncRNAs as diagnostic markers for PCa and summarizes recent progress in biosensing technologies, emphasizing electrochemical methods designed to identify ncRNAs associated with this cancer.
Zahra Oushyani Roudsari, Asma Vafadar, F. Altalbawy et al.· Clinica chimica acta; intern...· 0 citations
This work consolidates recent advances in circRNA research across preoperative, postoperative, drug resistance, and recurrence settings, providing a framework for non-invasive diagnosis, clinical decision-making, and outcome prediction in BC management.
Chun-Ming Wang, Xu Wang, Yu-Bo Liu et al.· Oncology Research· 0 citations
This review critically evaluates ML-driven frameworks for cancer diagnosis and prognosis across four ncRNA subclasses, namely miRNAs, lncRNAs, circRNAs, and piRNAs, while also acknowledging the biophysical and thermodynamic models that reinforce ncRNA bioinformatics.
This chapter explores the integration of LLMs with ncRNA biology, focusing on circRNAs, snoRNAs, and piRNAs in BC, and proposes a computational framework for biomarker identification.
Tamizhini Loganathan· Methods in molecular biology· 0 citations
An overview of recent progress in multi-omics approaches is provided and significant miRNA-, lncRNA-, and exosome-related biomarkers associated with the initiation, progression, and therapeutic response of breast cancer are emphasized.
Kamyar Bagheri, Amirhossein Saberi, Maryam Zand et al.· Cancer Treatment and Researc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.